Intact Fibroblast Growth Factor 23
EstablishedFGF23 excess causes rare hypophosphatemic bone diseases, now treated with a monoclonal antibody built to block it.
FGF23 controls how much phosphate the body keeps versus loses in urine. Too much of it causes rare bone-softening diseases. A newer drug, burosumab, was specifically designed to block this hormone directly — a good example of a biomarker becoming its own drug target.
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphate balance by promoting renal phosphate excretion and suppressing active vitamin D production.
Excess FGF23 causes X-linked hypophosphatemia (XLH), the most common inherited cause of FGF23-related hypophosphatemic rickets, and tumor-induced osteomalacia (TIO), a rare acquired condition from FGF23-secreting mesenchymal tumors.
Measured via serum immunoassay; TIO diagnosis is complicated by the difficulty of localizing the causative tumors, which are often small and hard to find even with extensive imaging, sometimes delaying diagnosis for years.
Burosumab, a monoclonal antibody that directly neutralizes FGF23, is now recommended first-line for XLH and is also FDA-approved for TIO — a rare case of a hormone-level biomarker having a drug built specifically to block it, replacing older, less effective oral phosphate and vitamin D supplementation.
TIO diagnosis remains genuinely difficult due to challenges localizing small, hard-to-find causative tumors.
- Orphanet Journal of Rare Diseases. (2025). X-linked hypophosphatemia and tumor-induced osteomalacia: diagnostic and therapeutic challenges in the era of burosumab.